pharma · Influenza, Human · Influenza
Seqirus USA
Seqirus (Australia) Pty Ltd
Seqirus USA clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 8
- Programs
- 9
- Drugs
- 19
- Patents
- 0
Seqirus USA projects
9 ClinicalTrials.gov programs sponsored by Seqirus USA.
Seqirus USA has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Seqirus (Australia) Pty Ltd
Influenza Virus
1 trial -
Influenza Virus Vaccine
Seqirus (Australia) Pty Ltd
Influenza
1 trial -
Investigational aQIVc
Seqirus (Australia) Pty Ltd
Influenza, Human
1 trial -
QIVc
Seqirus (Australia) Pty Ltd
Influenza, Human
1 trial -
V118_18
Seqirus (Australia) Pty Ltd
Influenza
1 trial -
aQIV or aTIV
Seqirus (Australia) Pty Ltd
Influenza, Human
1 trial -
H5N1 antigen combined with MF59 adjuvant
Seqirus (Australia) Pty Ltd
Influenza, Human
1 trial -
Trivalent influenza vaccine (TIVc)
Seqirus (Australia) Pty Ltd
Influenza
1 trial -
CSL Limited Influenza Vaccine
Seqirus (Australia) Pty Ltd
Influenza
1 trial
Frequently asked questions
How many clinical projects does Seqirus USA have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.